Data sourced from SEC EDGAR filings and third-party price providers. Scores, valuations, and metrics are algorithmic estimates. This is not investment advice. See our Terms and Methodology.
/
Data sourced from SEC EDGAR filings and third-party price providers. Scores, valuations, and metrics are algorithmic estimates. This is not investment advice. See our Terms and Methodology.
We are a clinical-stage biotechnology company developing novel and differentiated medicines for patients with autoimmune and inflammatory diseases, including serious and debilitating conditions with significant unmet medical need. These diseases are often chronic, biologically complex and difficult to treat, and many patients do not achieve durable disease control with currently available thera…
ROIC dropped from -42.30% to -47.87%, capital efficiency is deteriorating. Negative free cash flow of -$65M. The business is consuming cash, not generating it.
Profitability & Returns
Revenue
N/A
Net Income (TTM)
-$75M
▼ -31.0% YoY
Op. Margin
—
ROIC
-29.68%
▼ -5.6pp YoY
Cash Flow & Balance Sheet
FCF (TTM)
-$73M
▼ -130.6% YoY
Op. Cash Flow (TTM)
-$73M
▼ -130.9% YoY
Net Debt
-$226M
Net Cash Position
Cash & Equiv.
$226M
Continue Research